- Home
- TERN vs OLMA Comparison
TERN vs OLMA Comparison
Compare TERN & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- OLMA
- Stock Information
- Founded
- TERN 2017
- OLMA 2006
- Country
- TERN United States
- OLMA United States
- Employees
- TERN N/A
- OLMA N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- OLMA Health Care
- Exchange
- TERN Nasdaq
- OLMA Nasdaq
- Market Cap
- TERN 298.1M
- OLMA 289.0M
- IPO Year
- TERN 2021
- OLMA 2020
- Fundamental
- Price
- TERN $2.49
- OLMA $3.33
- Analyst Decision
- TERN Buy
- OLMA Strong Buy
- Analyst Count
- TERN 5
- OLMA 4
- Target Price
- TERN $18.38
- OLMA $26.75
- AVG Volume (30 Days)
- TERN 1.0M
- OLMA 910.6K
- Earning Date
- TERN 05-12-2025
- OLMA 03-18-2025
- Dividend Yield
- TERN N/A
- OLMA N/A
- EPS Growth
- TERN N/A
- OLMA N/A
- EPS
- TERN N/A
- OLMA N/A
- Revenue
- TERN N/A
- OLMA N/A
- Revenue This Year
- TERN N/A
- OLMA N/A
- Revenue Next Year
- TERN N/A
- OLMA N/A
- P/E Ratio
- TERN N/A
- OLMA N/A
- Revenue Growth
- TERN N/A
- OLMA N/A
- 52 Week Low
- TERN $2.46
- OLMA $3.28
- 52 Week High
- TERN $11.40
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- TERN 25.94
- OLMA 24.82
- Support Level
- TERN $3.07
- OLMA $3.28
- Resistance Level
- TERN $3.72
- OLMA $4.26
- Average True Range (ATR)
- TERN 0.22
- OLMA 0.33
- MACD
- TERN -0.04
- OLMA -0.05
- Stochastic Oscillator
- TERN 2.38
- OLMA 3.40
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.